Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (HNC)

Immunovative Therapies

Status and phase

Completed

Phase 2

Conditions

Squamous Cell Carcinoma of the Head and Neck

Cancer of Head and Neck

Treatments

Biological: AlloStim

Biological: AlloVax

Biological: CRCL

Study type

Interventional

Funder types

Industry

Identifiers

NCT01998542

ITL-010-HNC

Details and patient eligibility

About

The purpose of this study is to determine the safety and tumor debulking efficacy of personalized anti-cancer vaccine AlloVax(TM) in Subjects with confirmed recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who cannot be treated with surgery, chemotherapy or radiation. AlloVax(TM) is a personalized anti-cancer vaccine combining Chaperone Rich Cell Lysate (CRCL) as a source of tumor antigen prepared from patient's tumor and AlloStim(TM) as an adjuvant. The combination of CRCL and AlloStim(TM) is designed to provide cross-reactivity of alloantigen specific recognition with tumor-specific recognition. All the key components necessary to develop tumor-specific immunity by creating the inflammatory environment necessary to overcome the HNC immunosuppressive environment, breaking tumor immune tolerance, and provision of specific HNC antigens for generation of a specific adaptive anti-tumor response.

Full description

This is a Phase II study following up on a previous Phase I/II study in chemotherapy refractory metastatic disease with <90 day survival expectancy. In the Phase I/II study all patients progressed using RECIST criteria. However, 11/42 (26%) were alive at 1yr and 9/42 (21%) alive at 2 yr. Therefore, CT scans did not correlate with clinical presentation and "pseudo-progression" was suspected. This study was designed to select subjects with visible tumor burden on the head, neck or tongue that could be measured and photographed so as not to rely solely on CT scans to determine anti-tumor debulking efficacy. Subjects are initially primed with intradermal AlloStim(TM) injections creating systemic anti-allo-specific cellular immunity. Tumor biopsy samples taken prior to dosing were processed into personalized Chaperone Rich Cell Lysate (CRCL) vaccine containing enriched heat shock proteins which are believed to chaperone tumor-specific neoantigens . AlloStim(TM) was then injected with CRCL into primed subjects to create tumor-specific cellular immunity. Subsequently, subjects are infused with intravenous AlloStim(TM) to cause extravasation of memory cells to the tumor lesions. The protocol including intradermal AlloStim(TM) day 0, 3, 7, 10. Intradermal AlloStim(TM)+CRCL on days 14, 17, 21, 24. Intravenous AlloStim(TM) day 28. This experimental treatment schedule will continue for 3 cycles.

Enrollment

12 patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult males and female patients aged 18 to 70 years old, inclusive, at screening visit.
Patients with histopatholologically or cytologically confirmed diagnosis of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) that is incurable with surgery, chemotherapy or radiation. No nasopharyngeal primaries.
Patients must have a tumor safely accessable for biopsy resulting in a minimum of 0.1 g of tumor sample for CRCL processing.
Patients must have visible external tumors measurable with at least one lesion deemed to be safely accessible for serial biopsy.
ECOG ≤2.
The result of screening test were in the criteria:

6.1 Adequate organ function including:

A. Marrow:
- WBC >3000/mm3
- Platelets >100,000/mm3.
- Absolute neutrophil count ≥ 1,500/mm³
- Hemoglobin ≥ 10.0 g/dL (transfusion allowed)
B. Hepatic:
- Serum Total bilirubin < 2 x ULN mg/dL,
- ALT (SGPT) / AST (SGOT) ≤3 x upper limit of normal (ULN).
C. Renal:
- Serum creatinine (SCR) <2.0 x ULN, or
- Creatinine clearance (CCR) >30 mL/min.
6.2 All patients have a pre-study echocardiogram without significant abnormalities or Ejection fraction >50%.

6.3 All patients must be screened to be negative for HIV1, HIV2, HTLVI, HTLVII, HBV, HCV and RPR (syphilis).

6.4 Women of child-bearing potential must have a negative urine or serum pregnancy test result within 72 hours prior to the start of study drug administration.
All patients of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product.
Patients must have the ability to understand the study, its inherent risks, side effects and potential benefits and be able to give written informed consent to participate.

Exclusion criteria

Clinical evidence or radiological evidence of nasopharyngeal primaries.
Clinical evidence or radiological evidence of brain metastasis.
History of severe hypersensitivity to monoclonal antibody drugs or any contraindication to any of the study drugs.
Concomitant active autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, autoimmune thyroid disease, uveitis).
Prior experimental therapy or cancer vaccine treatment (e.g., dendritic cell therapy, heat shock vaccine).
Clinical requirement for systemic steroids or current immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 1 month of study entry.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, requiring parenteral antibiotics, symptomatic congestive heart failure, severe myocardial insufficiency, cardiac arrhythmia
All infections must be resolved and the patient must remain a febrile for seven days prior to being placed in the study.
History of blood transfusion reactions.
Psychiatric or addictive disorders or other condition that, in the opinion of the investigator, would preclude study participation.
Pregnant or breast feeding.